Potent functional antibody responses elicited by HIV-I DNA priming and boosting with heterologous HIV-1 recombinant MVA in healthy tanzanian adults

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Joachim, Agricola ^a,b   Nilsson, Charlotta ^b,c   Aboud, Said ^a   Bakari, Muhammad ^a   Lyamuya, Eligius F ^a   Robb, Merlin L ^d   Marovich, Mary A ^e   Earl, Patricia ^f   Moss, Bernard ^f   Ochsenbauer, Christina ^g   Wahren, Britta ^b   Mhalu, Fred ^a   Sandström, Eric ^b   Biberfeld, Gunnel ^b,c   Ferrari, Guido ^h   Polonis, Victoria R ^e  

^a MUHIMBILI UNIVERSITY OF HEALTH AND ALLIED SCIENCES   (Tanzania)

^b KAROLINSKA INSTITUTE   (Sweden)

^c SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^d Henry M Jackson Foundation for the Advancement of Military Medicine   (United States)

^e Military HIV Research Program   (United States)

^f NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^g University of Alabama at Birmingham   (United States)

^h DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FC RECEPTOR; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G; NEUTRALIZING ANTIBODY; PRIMER DNA; RECOMBINANT MODIFIED VACCINIA ANKARA; UNCLASSIFIED DRUG; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS ANTIGEN; RECOMBINANT VACCINE; VIRUS DNA;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CELL FUNCTION; CELL MEDIATED CYTOTOXICITY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; HUMAN; HUMAN EXPERIMENT; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR CLONING; NATURAL KILLER CELL; NORMAL HUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; TANZANIA; VACCINATION; VIRUS NEUTRALIZATION; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIGEN ANTIBODY REACTION; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; ENVELOPE GENE; GENETICS; IMMUNOLOGY; RANDOMIZED CONTROLLED TRIAL; SECONDARY IMMUNIZATION; STRUCTURAL GENE; VACCINIA VIRUS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

ADULT; AIDS VACCINES; ANTIBODIES, NEUTRALIZING; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGEN-ANTIBODY REACTIONS; DNA, VIRAL; DOUBLE-BLIND METHOD; GENES, ENV; GENES, GAG; HIV ANTIBODIES; HIV ANTIGENS; HIV-1; HUMANS; IMMUNIZATION, SECONDARY; KILLER CELLS, NATURAL; TANZANIA; VACCINATION; VACCINES, DNA; VACCINES, SYNTHETIC; VACCINIA VIRUS;

EID: 84929484560     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0118486     Document Type: Article

References (40)

1. Ferrantelli F, Ruprecht RM (2002) Neutralizing antibodies against HIV-back in the major leagues? Curr Opin Immunol 14:495-502. PMID: 12088685.
2. Mascola JR, Lewis MG, Stiegler G, Harris D, VanCott TC, et al. (1999) Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 73:4009-4018. PMID: 10196297.
3. Mascola JR, Stiegler G, VanCott TC, Katinger H, Carpenter CB, et al. (2000) Protection of macaques against vaginal transmission of a pathogenic HIV- 1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 6:207-210. PMID: 10655111.
4. Nishimura Y, Igarashi T, Haigwood NL, Sadjadpour R, Donau OK, et al. (2003) Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development. Proc Natl Acad Sci USA 100:15131-15136. PMID: 14627745.
5. Hessell AJ, Rakasz EG, Tehrani DN, Huber M, Weisgrau KL, et al. (2010) Broadly neutralizing monoclonal antibodies 2F5 and 4E10 directed against the human immunodeficiency virus type 1 gp41 membrane- proximal region protect against mucosal challenge by simian-human immunodeficiency virus SHIVBa-L. J Virol 84:1302-1313. doi:10.1128/JVI.01272-09 PMID: 19906907.
6. McElrath MJ, Haynes BF (2010) Induction of immunity to human immunodeficiency virus type 1 by vaccination. Immunity 33:342-355.
7. Hoxie JA (2010) Towards an antibody-based HIV-1 vaccine. Annu Rev Med 61:135-152. doi:10.1146/annurev.med.60.042507.164323 PMID: 19824826.
8. Tomaras GD, Haynes BF (2010) Strategies for eliciting HIV-1 inhibitory antibodies. Curr Opin HIV AIDS 5:421-427. doi:10.1097/COH.0b013e32833d2d45 PMID: 20978384.
9. Robinson HL (2013) Non-neutralizing antibodies in prevention of HIV infection. Expert Opin Biol Ther 13:197-207. doi:10.1517/14712598.2012.743527 PMID: 23130709.
10. Huber M, Trkola A (2007) Humoral immunity to HIV-1: neutralization and beyond. J Intern Med 262:5-25. PMID: 17598812.
11. Guan Y, Pazgier M, Sajadi MM, Kamin-Lewis R, Al-Darmarki S, et al. (2012) Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA E69-E78. doi:10.1073/pnas.1217609110 PMID: 23237851.
12. Ahmad R, Sindhu ST, Toma E, Morisset R, Vincelette J, et al. (2001) Evidence for a correlation between antibody dependent cellular cytotoxicity-mediating anti-HIV-1 antibodies and prognostic predictors of HIV infection. J Clin Immunol 21:227-233. PMID: 11403230.
13. Gómez-Román VR, Patterson LJ, Venzon D, Liewehr D, Aldrich K, et al. (2005) Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 174:2185-2189. PMID: 15699150.
14. Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, et al. (2009) Correlation of vaccine-elicited systemic and mucosal non-neutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. J Virol 83:791-801. doi:10.1128/JVI.01672-08 PMID: 18971271.
15. Alpert MD, Harvey JD, Lauer WA, Reeves RK, Piatak M Jr, et al. (2012) ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIVmac251 challenge. PLoS Pathog 8:e1002890. doi:10.1371/journal.ppat.1002890 PMID: 22927823.
16. Baum LL, Cassutt KJ, Knigge K, Khattri R, Margolick J, et al. (1996) HIV-1 gp120 specific antibodydependent cell mediated cytotoxicity correlates with rate of disease progression. J Immunol 157:2168-2173. PMID: 8757343.
17. Lambotte O, Ferrari G, Moog C, Yates NL, Liao H, et al. (2009) Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23:897-906. doi:10.1097/QAD.0b013e328329f97d PMID: 19414990.
18. Lambotte O, Pollara J, Boufassa F, Moog C, Venet A, et al. (2013) High antibody-dependent cellular cytotoxicity responses are correlated with strong CD8 T cell viral suppressive activity but not with B57 status in HIV-1 elite controllers. PLoS One 8.e74855. doi:10.1371/journal.pone.0074855.t002 PMID: 24086385.
19. Wren LH, Chung AW, Isitman G, Kelleher AD, Parsons MS, et al. (2012) Specific antibody-dependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 138:116-123.
20. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J (2012) HIV-specific antibodies capable of ADCC are common in breast milk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathog 8(6):e1002739. doi:0.1371/journal.ppat.1002739 PMID: 22719248.
21. Ljunggren K, Moschese V, Broliden PA, Giaquinto C, Quinti I, et al. (1990) Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 161:198-202. PMID: 2299204.
22. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, et al. (2012) Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med 366:1275-1286. doi:10.1056/NEJMoa1113425 PMID: 22475592.
23. Tomaras GD, Ferrari G, Shen X, Alam SM, Liao H- X, et al. (2013) Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 110:9019-9024. doi:10.1073/pnas.1301456110 PMID: 23661056.
24. Bakari M, Aboud S, Nilsson C, Francis J, Buma D, et al. (2011) Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania. Vaccine 29:8417-8428. doi:10.1016/j.vaccine.2011.08.001 PMID: 21864626.
25. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, et al. (2004) Comprehensive cross-subtype neutralization analysis of a panel of anti-human immunodeficiency virus type 1monoclonal antibodies. J Virol 78:13232-52. PMID: 15542675.
26. Choudry V, Zang M- Y, Sidorov IA, Louis JM, Harris I, et al. (2007) Cross-reactive HIV-1 neutralizing monoclonal antibodies selected by screening of an immune human phage library against an envelope glycoprotein (gp140) isolated from a patient (R2) with broadly neutralizing antibodies. Virology 363:79-90. PMID: 17306322.
27. Brown BK, Wieczorek L, Sanders-Buell E, Rosa Borges A, Robb ML, et al. (2008) Cross-clade neutralization patterns among HIV-1 strains from the six major clades of the pandemic evaluated and compared in two different models. Virology 375:529-538. doi:10.1016/j.virol.2008.02.022 PMID: 18433824.
28. Polonis VR, Brown BK, Rosa Borges A, Zolla-Pazner S, Dimitrov DS, et al. (2008) Recent advances in the characterization of HIV-1 neutralization assays for standardized evaluation of the antibody response to infection and vaccination. Virology 375:315-320. doi:10.1016/j.virol.2008.02.007 PMID: 18367229.
29. Fenyö EM, Heath A, Dispinseri S, Holmes H, Lusso P, et al. (2009) International network for comparison of HIV neutralization assays: The Neut Net report. PLoS One 4: e4505. doi:10.1371/journal.pone.0004505 PMID: 19229336.
30. Brown BK, Wieczorek L, Kijak G, Lombardi K, Currier J, et al. (2012) The role of natural killer (NK) cells and NK cell receptor polymorphisms in the assessment of HIV-1 neutralization. PLoS One 7(4): e29454. doi:10.1371/journal.pone.0029454 PMID: 22509241.
31. Edmonds TG, Ding H, Yuan X, Wei Q, Smith KS, et al. (2010) Replication competent molecular clones of HIV-1 expressing Renilla luciferase facilitate the analysis of antibody inhibition in PBMC. Virology 408:1-13. doi:10.1016/j.virol.2010.08.028 PMID: 20863545.
32. Pollara J, Hart L, Brewer F, Pickeral J, Packard BZ, et al. (2011) High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry A 79:603-612. doi:10.1002/cyto.a.21084 PMID: 21735545.
33. Pollara J, Bonsignori M, Moody MA, Liu P, Alam SM, et al. (2014) HIV-1 Vaccine-Induced C1 and V2 Env-Specific Antibodies Synergize for Increased Antiviral Activities J Virol 88:7715-7726. doi:10.1128/JVI.00156-14 PMID: 24807721.
34. Nilsson C, Godoy-Ramirez K, Hejdeman B, Bråve A, Gudmundsdotter L, et al. (2014) Broad and potent cellular and humoral immune responses after a second late HIV-MVA vaccination in HIV-DNA primed and HIV-MVA boosted Swedish vaccinees. AIDS Res Hum Retroviruses 30:299-311. doi:10.1089/AID.2013.0149 PMID: 24090081.
35. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, et al. (2009) Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 361: 2209-2220. doi:10.1056/NEJMoa0908492 PMID: 19843557.
36. Florese RH, Demberg T, Xiao P, Kuller L, Larsen K, et al. (2009) Contribution of non-neutralizing vaccine- elicited antibody activities to improved protective efficacy in rhesus macaques immunized with Tat/Env compared with multigenic vaccine. J Immunol. 182:3718-3727 doi:10.4049/jimmunol.0803115 PMID: 19265150.
37. Xiao P, Zhao J, Patterson J, Brocca-Cofano E, Venzon D, et al. (2010) Multiple vaccine-elicited nonneutralizing anti envelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 84: 7161-7173. doi:10.1128/JVI.00410-10 PMID: 20444898.
38. Currier JR, Ngauy V, de Souza MS, Ratto-Kim S, Cox JH, et al. (2010) Phase I safety and immunogenicity evaluation of MVA-CMDR, a multigenic, recombinant modified vaccinia Ankara HIV-1 vaccine candidate. PLoS ONE 5(11): e13983. doi:10.1371/journal.pone.0013983 PMID: 21085591.
39. Karnasuta C, Robert M, Paris RM, Cox J H, Nitayaphan S, et al. (2005) Antibody-dependent cellmediated cytotoxic responses in participants in a phase I/II ALVAC-HIV/AIDSVAX B/E prime-boost HIV-1 vaccine trial in Thailand. Vaccine 23:2522-2529. PMID: 15752839.
40. Sun Y, Asmal M, Lane S, Permar SR, Schmidt SD, et al. (2011) Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 85:6906-6912. doi:10.1128/JVI.00326-11 PMID: 21593181.